Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Inovio Pharmaceuticals (INO)
NASDAQ:INO
RESEARCH TOOLSreports
Holding INO?
Track your performance easily
INO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.85 - $14.75
Previous Close$4.13
Volume719.41K
Average Volume (3M)335.45K
Market Cap
$107.79M
Enterprise Value$35.43M
Total Cash (Recent Filing)$84.80M
Total Debt (Recent Filing)$12.45M
Price to Earnings (P/E)―
Beta1.92
Next Earnings
Mar 04, 2025EPS Estimate
-$0.92Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.48
Shares Outstanding26,099,991
10 Day Avg. Volume492,344
30 Day Avg. Volume335,454
Standard Deviation0.29
R-Squared0.02
Alpha-0.00014
Financial Highlights & Ratios
Price to Book (P/B)1.41
Price to Sales (P/S)517.09
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue174.20
Enterprise Value/Gross Profit42.59
Enterprise Value/Ebitda-0.32
Forecast
1Y Price Target
$11.00Price Target Upside166.34% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
Inovio Pharmaceuticals News
PremiumCompany Announcements
Inovio Pharmaceuticals Advances DNA Medicine DevelopmentOwnership Overview
0.84% Insiders
8.99% Mutual Funds
8.04% Other Institutional Investors
71.97% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
INO FAQ
What was Inovio Pharmaceuticals’s price range in the past 12 months?
Inovio Pharmaceuticals lowest stock price was $3.85 and its highest was $14.75 in the past 12 months.
What is Inovio Pharmaceuticals’s market cap?
Currently, no data Available
When is Inovio Pharmaceuticals’s upcoming earnings report date?
Inovio Pharmaceuticals’s upcoming earnings report date is Mar 04, 2025 which is in 98 days.
How were Inovio Pharmaceuticals’s earnings last quarter?
Inovio Pharmaceuticals released its earnings results on Nov 14, 2024. The company reported -$0.89 earnings per share for the quarter, beating the consensus estimate of -$1.15 by $0.26.
Is Inovio Pharmaceuticals overvalued?
According to Wall Street analysts Inovio Pharmaceuticals’s price is currently Undervalued.
Does Inovio Pharmaceuticals pay dividends?
Inovio Pharmaceuticals does not currently pay dividends.
What is Inovio Pharmaceuticals’s EPS estimate?
Inovio Pharmaceuticals’s EPS estimate is -$0.92.
How many shares outstanding does Inovio Pharmaceuticals have?
Inovio Pharmaceuticals has 26,099,990 shares outstanding.
What happened to Inovio Pharmaceuticals’s price movement after its last earnings report?
Inovio Pharmaceuticals reported an EPS of -$0.89 in its last earnings report, beating expectations of -$1.15. Following the earnings report the stock price went down -10.692%.
Which hedge fund is a major shareholder of Inovio Pharmaceuticals?
Among the largest hedge funds holding Inovio Pharmaceuticals’s share is GMT Capital Corp. It holds Inovio Pharmaceuticals’s shares valued at 729K.
---
Inovio Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.00 (166.34% Upside)
$11.00 (166.34% Upside)
Blogger Sentiment
Bullish
INO Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 189.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.4%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.85%
12-Months-Change
Fundamentals
Return on Equity
-106.64%
Trailing 12-Months
Asset Growth
-44.56%
Trailing 12-Months
Company Description
Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc. is a late-stage biotechnology company, which engages in the discovery, development, and commercialization of DNA-based immunotherapies and vaccines. Its drug candidates include SynCon immunotherapies which helps break the immune system's tolerance of cancerous cells; and CELLECTRA delivery system which facilitates optimized cellular uptake of the SynCon immunotherapies. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.
---
INO Earnings Call
Q3 2024
0:00 / 0:00
---
INO Stock 12 Month Forecast
Average Price Target
$11.00
▲(166.34% Upside)
Technical Analysis
Best Analysts Covering INO
1 Year
1 Year Success Rate
0/10 ratings generated profit
1 Year Average Return
-58.12%
reiterated a buy rating 9 days ago
Copying Hartaj Singh's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -58.12% per trade.
---